Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
58 results about "Dengue virus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dengue virus (DENV) is the cause of dengue fever. It is a mosquito-borne, single positive-stranded RNA virus of the family Flaviviridae; genus Flavivirus. Five serotypes of the virus have been found, all of which can cause the full spectrum of disease. Nevertheless, scientists' understanding of dengue virus may be simplistic, as rather than distinct antigenic groups, a continuum appears to exist. This same study identified 47 strains of dengue virus. Additionally, coinfection with and lack of rapid tests for zika virus and chikungunya complicate matters in real-world infections.
Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
ActiveUS9944598B2Strong antiviral activityPromote efficient proliferationOrganic active ingredientsOrganic chemistry methodsMedicineViral infection
Owner:JANSSEN PHARMA INC +1
Monoclonal antibodies that bind or neutralize dengue virus
The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and / or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
Owner:UNITED STATES OF AMERICA
Immunization Compositions and Methods
ActiveUS20110189226A1SsRNA viruses negative-senseBacterial antigen ingredientsSerotypeNeutralizing antibody
The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and / or VZV virus.
Owner:SANOFI PASTEUR SA
Mono- or Di-Substituted Indole Derivatives As Dengue Viral Replication Inhibitors
ActiveUS20180256544A1Strong antiviral activityPromote efficient proliferationOrganic active ingredientsOrganic chemistryMedicineViral infection
The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections.The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Owner:KATHOLIEKE UNIV LEUVEN +2
Mono- or Di-Substituted Indole Derivatives As Dengue Viral Replication Inhibitors
ActiveUS20180256545A1Strong antiviral activityPromote efficient proliferationOrganic active ingredientsOrganic chemistry methodsMedicineViral infection
The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections.The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Owner:JANSSEN PHARMA INC +1
Nucleic acid detection kit for Zika virus, dengue fever virus and Chikungunya virus, and application of the kit
ActiveCN108330210ASolve the problem of not being able to detect three viruses simultaneously in one reactionSimple and fast operationMicrobiological testing/measurementAgainst vector-borne diseasesZika virusPositive control
The invention discloses a nucleic acid detection kit for Zika virus, dengue fever virus and Chikungunya virus, and an application of the kit, wherein the kit includes: a RT-PCR reaction solution, an enzyme mixture liquid, a Zika virus / dengue fever virus / Chikungunya virus / endogenous reference gene quadruple reaction solution, a positive control, and a blank control. The kit can simultaneously detect the Zika virus, dengue fever virus and Chikungunya virus in one reaction and solves a problem that an in-vitro detection kit cannot simultaneously detect the Zika virus, dengue fever virus and Chikungunya virus in one reaction tube; besides, the detection kit is high in specificity and sensitivity, has simple operation, excellent repeatability and quick and objection detection results. The invention provides an effective technical means for in-vitro detection of the Zika virus, dengue fever virus and Chikungunya virus.
Owner:GUANGZHOU CENT FOR DISEASE CONTROL & PREVENTION (GUANGZHOU HYGIENE INSPECTION CENT GUANGZHOU CENT FOR FOOD SAFETY RISK SURVEILLANCE & ASSESSMENT INST OF PUBLIC HEALTH OF GUANGZHOU MEDICAL UNIV) +1
Mono- or di-substituted indoles as dengue viral replication inhibitors
ActiveUS10206902B2Strong antiviral activityPromote efficient proliferationOrganic active ingredientsComponent separationMedicineViral infection
The present invention concerns mono- or di-substituted indole compounds of formula (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Owner:JANSSEN PHARMA INC +1
Immune dengue plus
InactiveUS20060029659A1Improve survival rateEnhancing blood platelet builderBiocideAnthropod material medical ingredientsThrombopoiesisObserved Survival
An immune enhancing blood platelet builder that increases the survival rate of the patient against the duration of the dengue fever virus in the body.
Owner:PANZARDI MICHAEL
Methods and materials for the detection of dengue virus infection
ActiveUS8920804B2Easy to useQuick controlViral antigen ingredientsMicrobiological testing/measurementStructural glycoproteinPolyclonal antibodies
The present invention provides monoclonal antibodies that are specific for the Dengue non-structural glycoprotein NS1 in monomeric and / or oligomeric (primarily dimeric) form, together with methods, including ELISA and lateral flow assays, that employ the disclosed antibodies for the early detection of Dengue virus infection. Diagnostic kits for the detection of Dengue infection are also provided, such kits including the disclosed monoclonal and / or polyclonal antibodies.
Owner:INBIOS INT
Repair traditional Chinese medicine used for treating blood cell infected by flaviviridae
InactiveCN105920380AEffective preventionEffective therapeuticNervous disorderDigestive systemMedicinal herbsDisease
The invention relates to the field of traditional Chinese medicine, and discloses a repair traditional Chinese medicine used for treating blood cell infected by flaviviridae. The traditional Chinese medicine is prepared from: by weight, herba tubocapsici anomali 30g-80g, cymbopogon citratus 20g-50g, camellia flower 10g-30g, citrus aurantium flower 10g-30g, bitter gourd 20g-50g, mint 20g-50g, phellodendron amurense 10g-30g, cypress leaf 10g-30g, salix leaf 10g-30g, persimmon leaf 15g-35g, perilla nankinensis 10g-20g, radix sophorae flavescentis 30g-60g, eleusine indica 25g-80g, syzygium aromaticum 10g-30g, lonicera japonica 30g-80g, agastache rugosus 20g-50g, portulaca oleracea 10g-30g, glycyrrhiza 5g-15g, chrysanthemum 10g-35g, and foeniculum vulgare 10g-35g. The traditional Chinese medicine has cure effect of the diseases such as dengue, Zika virus, encephalitis, hepatitis and liver cancer infected by flaviviridae spreading, can treat and repair the blood cell from the source, has prophylaxis and treatment effect on flaviviridae diseases, is without any toxicity and side effects, and can improve the cure rate and cure efficiency of patients.
Owner:林家希
Kit for detecting dengue fever virus, and special-purpose amplification primer and probe for the same
InactiveCN101100694AEasy to operateStrong specificityMicrobiological testing/measurementAgainst vector-borne diseasesAgricultural scienceInducer
A kit and special alkali inducers for amplification and probes can be used to check out dengue fever virus. The inducers consist of a couple of opposite directions. One is of sequence shown in No.1, another is of sequence shown in No.2, and probes shown in No.3. The process has advantages, e.g. quick action, simple, high sensitivity and specification in detection of dengue fever virus I, II, III and IV.
Owner:SHENZHEN INT TRAVEL HEALTHCARE CENT
Primer group, kit and method for rapidly identifying 1 type dengue fever virus
ActiveCN103173568AStrong specificityHigh sensitivityMicrobiological testing/measurementMicroorganism based processesReverse transcriptaseReaction tube
The invention discloses a primer group, a kit and a method for rapidly identifying a 1 type dengue fever virus. The detection primer group comprises a pair of outer primers, a pair of inner primers and a pair of loop primers; and the detection kit comprises primer liquor, reaction liquor, DNA (deoxyribonucleic acid) polymerase, reverse transcriptase, a comparison agent and a color developing agent. The detection method comprises steps that: a sample RNA (ribonucleic acid) template is amplified through extracting a virus RNA to be detected and utilizing the reverse transcription activity of the reverse transcriptase by adopting six specific primers and the DNA polymerase with the strand displacement activity at 60-65 DEG C, and whether the sample RNA template is required to be amplified or not depends on the color change in a reaction tube in which the color developing agent is added. The method has the advantages of being efficient and rapid, convenient to operate, convenient to identify, having high specificity and sensitivity, and being applicable to detection at site, and the like, thus being applicable to promotion and application.
Owner:SUN YAT SEN UNIV
Multiplex-fluorescence PCR (Polymerase Chain Reaction) detection kit and application thereof
InactiveCN103305633AGuaranteed heightGuaranteed FeaturesMicrobiological testing/measurementMicroorganism based processesDiseaseNucleotide
The invention relates to the technical field of biological detection, and in particular relates to a primer, a probe and a kit used for detecting dengue fever, chikungunya and yellow fever virus through a single tube by the multiplex-fluorescence PCR (Polymerase Chain Reaction). The primer and probe used for detecting the dengue fever, chikungunya and yellow fever virus through the multiplex-fluorescence PCR have nucleotide sequences as shown in SEQ ID NO: 1-9; the multiplex PCR detection kit for detecting the dengue fever, chikungunya and yellow fever virus comprises multiplex-fluorescence PCR detection mixed liquid which contains the primer and probe mentioned above. The kit, primer and probe can quickly detect the dengue fever virus, chikungunya virus and yellow fever virus, have the advantages of being simple and convenient to operate, high in sensitivity and outstanding in specificity, and can timely find out and confirm a suspect case so as to improve the monitoring level on such diseases.
Owner:浙江国际旅行卫生保健中心 +1
Binding protein of NS1 protein
ActiveCN109134647ARealize detectionHigh sensitivityImmunoglobulins against virusesImmunoassaysHeavy chainTrue positive rate
The invention provides an isolated binding protein having an antigen binding structural domain which is bound with NS1 protein. The isolated binding protein comprises specific heavy chain CDR and light chain CDR, can recognize and bind with the NS1 protein specifically, has high flexibility and specificity, and can realize detection on dengue fever virus. The way of utilizing mouse peritoneal induced hybridoma to produce the binding protein is omitted, and thus, production difficulty of the binding protein is reduced while antibody function thereof is much stable.
Owner:DONGGUAN PENGZHI BIOTECH CO LTD
Antiviral compounds
PendingUS20210284669A1Organic active ingredientsGroup 5/15 element organic compoundsZika virusRespiratory syncytial virus (RSV)
The present disclosure provides a compound of Formula I:which is useful in treating a variety of diseases, such as diseases caused by respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, HCV and / or HBV infections.
Owner:GILEAD SCI INC
Compositions and methods for the rapid differential detection of zika virus
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
ActiveUS10316066B2SsRNA viruses negative-senseSsRNA viruses positive-senseStructural proteinPolynucleotide
The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and / or treatment of a dengue virus infection.
Owner:INST PASTEUR +2
False virosome vaccine with recombinant replicon of dengue fever virus as carrier
InactiveCN1524952AImprove effectivenessEffective immunityViral antigen ingredientsViral/bacteriophage medical ingredientsDendritic cellDengue virus
The invention provides a false virus granule vaccine with dengue fever virus recombination replicon as a core and method for preparation, wherein the vaccine can express antigens with high efficiency in the affected cells, the antigen can be extracted effectively with good immunity effect. The vaccine can be used for preventing and treating tumor and virosis.
Owner:上海天甲生物医药有限公司 +2
Substituted indoline derivatives as dengue viral replication inhibitors
ActiveUS11180450B2Strong antiviral activityPromote efficient proliferationOrganic active ingredientsOrganic chemistry methodsPharmaceutical drugIndoline
Owner:JANSSEN PHARMA INC +1
Quick high-flux dengue fever virus detection typing method
ActiveCN104480221AAccurate detectionShorten the timeMicrobiological testing/measurementMicroorganism based processesSerum igeRNA extraction
The invention relates to a quick high-flux dengue fever virus detection typing method. The detection method integrates the two powerful molecular biology techniques of polymerase chain reaction (PCR) and microarray, and directly fixes the PCR hybridized probe to the hybridization bin of the microarray in the same chip as the PCR reaction chamber. The detection method comprises the following steps: specimen RNA (ribonucleic acid) extraction, PCR amplification, hybridization, cleaning and result interpretation. The method can perform quick and sensitive detection and typing on dengue fever virus (serum type I, II, III and IV). The method can greatly enhance the detection efficiency of the front-line inspection health officers of import-export ports, reduce the workload and maximally solve the problem of possible undetected positive in the traditional detection method, thereby maximally preventing the dengue epidemic situation from generation.
Owner:SHANGHAI ENTRY EXIT INSPECTION & QUARANTINE BUREAU OF P R C
DNA molecules producing custom designed replicating and non-replicating negative stranded RNA viruses and uses there of
ActiveUS20190211355A1Improving oncolytic potencyEasy to detectSsRNA viruses negative-senseSsRNA viruses positive-senseNegative strandCancer cell
This invention comprises: compositions comprising a derivative, plasmids, a reagent kit and methods of making these compositions a derivative, vaccine- and non-vaccine-compositions of above for causing death of cancer cells that form part of a tumour and virus infected Dengue, Measles and other diseased cells; the derivative comprising replicating as well as non-replicating derivatives of an attenuated negative stranded RNA virus belonging to family paramyxoviridae, including Measles Virus, comprising a single additional transcriptional unit carrying either only one or two or more non-viral genes, and the non-replicating derivatives being free from contaminating replicating Measles Virus (b) a Measles Virus packaging cell line for making above compositions, expressing the M, F and H proteins of MV stably. And (c) a reagent kit for producing the Measles Virus derivatives described above.
Owner:JOSHI VISHWAS DATTATRAYA
Use of a quinazoline compound in preparing a medicament against flaviviridae virus
InactiveUS20130261139A1Strong inhibitory activityBiocideOrganic active ingredientsHepatitis c viralDiaminoquinazoline
Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Methods for attenuating dengue virus infection
Owner:UNIV OF SOUTH FLORIDA
Application of Viola yedoensis in preparation of drug for preventing and treating infection of dengue II viruses
The invention relates to application of Viola yedoensis in preparation of a drug for preventing and treating infection of dengue II viruses. According to the application, a Viola yedoensis aqueous extract is capable of obviously inhibiting the dengue II viruses and can be used for treating the drug for preventing and treating the infection of the dengue II viruses. The drug for preventing and treating the infection of the dengue II viruses is a clinically acceptable solid or liquid oral preparation prepared from the Viola yedoensis aqueous extract and a conventional dosage of medically acceptable auxiliary materials.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Antiviral compounds
PendingUS20210284670A1Organic active ingredientsGroup 5/15 element organic compoundsDiseaseZika virus
The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.
Owner:GILEAD SCI INC
Vaccine for human papiloma virus
InactiveCN1524951AImprove effectivenessEffective immunityViral antigen ingredientsViral/bacteriophage medical ingredientsDendritic cellDengue virus
The invention provides a false virus granule vaccine with dengue fever virus recombination replicon as a core and method for preparation, wherein the vaccine can express antigens with high efficiency in the affected cells, because of the characteristic of affecting dendritic cell of the dengue fever virus, the antigen can be extracted effectively with good immunity effect. The vaccine can be used for preventing and treating tumor and virosis.
Owner:上海天甲生物医药有限公司 +2
Substituted indoline derivatives as dengue viral replication inhibitors
The present invention relates to substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine,more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of thecompounds.
Owner:JANSSEN PHARMA NV +1
Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
ActiveUS10696632B2Strong antiviral activityPromote efficient proliferationOrganic active ingredientsOrganic chemistryPharmaceutical drugViral infection
Owner:KATHOLIEKE UNIV LEUVEN +2
Use of serotonergic drugs to treat virus-induced thrombocytopenia
ActiveUS20200352947A1Prevented and ameliorated developmentPreventing the uptake of serotoninOrganic active ingredientsAntiviralsReceptorSerotonin uptake
The present invention relates to the use of serotonergic compounds for the treatment of virus-induced thrombocytopenia. More particularly, the invention relates to methods of treating thrombocytopenia by blocking serotonin activity. For example, inhibitors of receptor 5HT2A and / or receptor 5HT1A and / or inhibitors of mast cell degranulation and / or inhibitors of serotonin uptake may be used. Preferably, the thrombocytopenia is induced by dengue or Japanese Encephalitis virus, and the inhibitors are preferably ketanserin, WAY-100135, sarpogrelate, or fluoxetine.
Owner:NAT UNIV OF SINGAPORE
Use of a quinazoline compound in preparing a medicament against flaviviridae virus
InactiveUS9133138B2Strong inhibitory activityOrganic active ingredientsBiocideDiaminoquinazolinePharmaceutical drug
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com